Switch theme
Sign up to access all valuation multiples
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
2012
217
LTM Revenue $194M
LTM EBITDA $54.6M
$181M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biote has a last 12-month revenue (LTM) of $194M and a last 12-month EBITDA of $54.6M.
In the most recent fiscal year, Biote achieved revenue of $197M and an EBITDA of $15.6M.
Biote expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biote valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $194M | XXX | $197M | XXX | XXX | XXX |
| Gross Profit | $139M | XXX | $139M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $54.6M | XXX | $15.6M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $35.4M | XXX | $31.6M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $15.3M | XXX | $3.2M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $68.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Biote's stock price is $3.
Biote has current market cap of $92.5M, and EV of $181M.
See Biote trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $181M | $92.5M | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Biote has market cap of $92.5M and EV of $181M.
Biote's trades at 0.9x EV/Revenue multiple, and 11.6x EV/EBITDA.
Equity research analysts estimate Biote's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biote has a P/E ratio of 6.0x.
See valuation multiples for Biote and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $92.5M | XXX | $92.5M | XXX | XXX | XXX |
| EV (current) | $181M | XXX | $181M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBIT | 5.1x | XXX | 5.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.0x | XXX | 29.3x | XXX | XXX | XXX |
| EV/FCF | 6.7x | XXX | 4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiote's last 12 month revenue growth is 2%
Biote's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Biote's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biote's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biote and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 138% | XXX | XXX | XXX |
| Rule of 40 | 7% | XXX | 10% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| National Healthcare Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Addus HomeCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Amedisys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biote acquired XXX companies to date.
Last acquisition by Biote was XXXXXXXX, XXXXX XXXXX XXXXXX . Biote acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Biote founded? | Biote was founded in 2012. |
| Where is Biote headquartered? | Biote is headquartered in United States of America. |
| How many employees does Biote have? | As of today, Biote has 217 employees. |
| Is Biote publicy listed? | Yes, Biote is a public company listed on NAS. |
| What is the stock symbol of Biote? | Biote trades under BTMD ticker. |
| When did Biote go public? | Biote went public in 2022. |
| Who are competitors of Biote? | Similar companies to Biote include e.g. National Healthcare Corp, Regis Healthcare, Maternus-Kliniken, Addus HomeCare. |
| What is the current market cap of Biote? | Biote's current market cap is $92.5M |
| What is the current revenue of Biote? | Biote's last 12 months revenue is $194M. |
| What is the current revenue growth of Biote? | Biote revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Biote? | Current revenue multiple of Biote is 0.9x. |
| Is Biote profitable? | Yes, Biote is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biote? | Biote's last 12 months EBITDA is $54.6M. |
| What is Biote's EBITDA margin? | Biote's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Biote? | Current EBITDA multiple of Biote is 3.3x. |
| What is the current FCF of Biote? | Biote's last 12 months FCF is $27.1M. |
| What is Biote's FCF margin? | Biote's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Biote? | Current FCF multiple of Biote is 6.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
